Brexpiprazole With Antidepressants for Agitation in Alzheimer's Dementia: Post Hoc Analysis.
C Brendan Montano, Sanjeda R Chumki, David Wang et al.
✦ AI-curated · Sources linked
In 30 seconds
This post hoc analysis of two Phase 3 randomized controlled trials evaluated the efficacy and safety of brexpiprazole for agitation in Alzheimer's dementia, both with and without concomitant antidepressants. Brexpiprazole significantly improved agitation symptoms, with a least squares mean difference of -12.1 in the CMAI Total score for those on antidepressants and -2.93 for those not on them.
Key findings
- Brexpiprazole improved CMAI Total score by -12.1 in participants on antidepressants.
- In participants without antidepressants, the improvement was -2.93 in CMAI Total score.
- Falls were the only treatment-emergent adverse event reported in ≥5% of participants on antidepressants.
Why it matters
The findings suggest that brexpiprazole may be an effective option for managing agitation in Alzheimer's dementia, potentially enhancing patient care and quality of life. Understanding its safety profile is also crucial for clinicians treating this vulnerable population.